nicefit-on: a study under routine clinical practice in taiwan to observe the long-term outcome of people with certain types of lung disease (pf-ild, ssc-ild, ipf) who start treatment with nintedanib

Conditions: Idiopathic Pulmonary Fibrosis

Summary: to better understand the clinical characteristics of idiopathic pulmonary fibrosis (ipf) / systemic sclerosis-associated-interstitial lung disease (ssc-ild)/ progressive fibrosing interstitial lung disease (pf-ild) patients treated with nintedanib and biomarkers associated with the disease course, a non-interventional, 3-year, prospective study will be conducted to collect the long-term real-world clinical data on ipf/ssc-ild/pf-ild patients newly administered with nintedanib in taiwan


Eligibility criteria:
inclusion criteria: this study plans to enroll approximately 500 patients with ipf/ssc-ild/pf-ild who newly initiate nintedanib per physicians' discretion within 6 months before participating in the study. ipf cohort: * diagnosed with ipf during the prior 6 months before study enrollment, based on the 2018 ats/ers/jrs/alat guideline * patient ≥ 40 years of age * newly initiating nintedanib within 6 months prior to participating in the study * providing written informed consent prior to participating in the study * having further follow-up possibility with participating physician during the planned study period * ability to read and write in local language ssc-ild cohort: * diagnosed with ssc-ild during the prior 6 months before study enrollment, based on 2013 acr/eular * patient ≥ 20 years of age * newly initiating nintedanib or not receiving nintedanib per physician's discretion (for patients who diagnosed with ssc-ild but are not treated with nintedanib on physician's discretion, they will apply the same inclusion criteria, with baseline characteristics collected only) within 6 months prior to participating in the study * providing written informed consent prior to participating in the study * having further follow-up possibility with participating physician during the planned study period * ability to read and write in local language pf-ild cohort: * diagnosed with pf-ild (pf-ild patients will be enrolled only after nintedanib acquires the label approval from tfda) during the prior 6 months before study enrollment. the definition of pf-ild diagnosis is as follows: --patients who have ild with a progressive phenotype, but are not diagnosed with ipf, per physician's judgment. the pathophysiology in these patients is characterized by self-sustaining fibrosis and a deterioration in lung function over time, with worsening respiratory symptoms, resistance to immune-modulatory therapies, and ultimately early mortality. * patient ≥ 20 years of age * newly initiating nintedanib or not receiving nintedanib per physician's discretion (for patients who diagnosed with pf-ild but are not treated with nintedanib on physician's discretion, they will apply the same inclusion criteria, with baseline characteristics collected only) within 6 months prior to participating in the study * providing written informed consent prior to participating in the study * having further follow-up possibility with participating physician during the planned study period * ability to read and write in local language exclusion criteria: - lung transplantation expected within the next 6 months. --included in ongoing interventional trials